Compare Gap Inc (GAP) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gap Inc vs Inovio Pharmaceuticals Inc — how do they compare? Gap Inc trades at $20.49 (market cap $7.55B), while Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M). The key difference: Gap Inc is far larger — about 96.1× Inovio Pharmaceuticals Inc's market cap, and Gap Inc pays a 3.34% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| GAP | INO | |
|---|---|---|
Market Cap | $7.55B | $78.55M |
Sector | Consumer Cyclical | Health |
52-Week High | $29.13 | $2.87 |
52-Week Low | $18.35 | $0.66 |
Enterprise Value | $10.63B | $49.56M |
Dividend Yield | 3.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gap Inc. (GAP) trades at $21.51, up 5.08% today, showing strong momentum amid a bullish technical outlook. The stock presents compelling value with a P/E of 8.32 and P/S of 0.52, well below industry averages. Recent earnings have mostly beaten expectations, with Q1 2026 EPS of $0.38 exceeding estimates. Revenue growth has stabilized at $15.1B for 2025, while net income margin improved to 5.59%. The company maintains solid cash flow generation with $464M net cash flow in 2025.
Gap offers attractive valuation upside with a consensus price target of $26.09 (21% potential). However, risks include ongoing investigations by Pomerantz Law Firm and competitive pressures in retail. The turnaround story appears credible with nine consecutive positive comps, but execution risks remain. Current technical indicators suggest the stock is approaching overbought territory with RSI above 70.
INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.
Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
